Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates
10:25pm, Tuesday, 22'nd Feb 2022 Zacks Investment Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -13.41% and 1.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics GAAP EPS of -$2.03 misses by $0.34, revenue of $165.2M beats by $4.12M
09:03pm, Tuesday, 22'nd Feb 2022 Seeking Alpha
PTC Therapeutics press release (NASDAQ:PTCT): Q4 GAAP EPS of -$2.03 misses by $0.34.Revenue of $165.2M (+39.0% Y/Y) beats by $4.12M.
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
09:01pm, Tuesday, 22'nd Feb 2022 PR Newswire
SOUTH PLAINFIELD, N.J., Feb. 22, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2021. "It is gratifying to see that after two years of investment in the innovation
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates
06:28pm, Tuesday, 22'nd Feb 2022
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -13.41% and 1.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics Q4 2021 Earnings Preview (NASDAQ:PTCT)
10:35pm, Monday, 21'st Feb 2022 Seeking Alpha
PTC Therapeutics (NASDAQ:PTCT) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close.The consensus EPS Estimate is -$1.55 (-43.5% Y/Y) and the
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
01:06pm, Sunday, 20'th Feb 2022 Benzinga
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
On the regulatory front, the Food and Drug A
Is a Surprise Coming for PTC Therapeutics (PTCT) This Earnings Season?
01:46pm, Friday, 18'th Feb 2022 Zacks Investment Research
PTC Therapeutics (PTCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Surprise Coming for PTC Therapeutics (PTCT) This Earnings Season?
10:05am, Friday, 18'th Feb 2022
PTC Therapeutics (PTCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?
08:01pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics (PTCT) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
08:21pm, Wednesday, 12'th Jan 2022 Seeking Alpha
Strength Seen in PTC Therapeutics (PTCT): Can Its 5.1% Jump Turn into More Strength?
01:19pm, Tuesday, 11'th Jan 2022 Zacks Investment Research
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
Strength Seen in PTC Therapeutics (PTCT): Can Its 5.1% Jump Turn into More Strength?
10:00am, Tuesday, 11'th Jan 2022
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
PTC Therapeutics upbeat 2022 revenue guidance lifts shares
06:13pm, Monday, 10'th Jan 2022 Seeking Alpha
PTC Therapeutics'' announcement that it expects $700M-$750M in revenue this year is propelling shares higher.
PTC Therapeutics 2021 Net Product Revenue Up 29% - Quick Facts
12:40pm, Monday, 10'th Jan 2022 Business Insider Markets
(RTTNews) - PTC Therapeutics, Inc. (PTCT) reported 2021 total unaudited net revenue of approximately $536 million, representing 41% year-over-year growth. Net product revenue was $429 million, 29% year-over-year growth. The company recorded strong year-over-year growth for the Duchenne muscular dystrophy franchise, with unaudited net product
PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
08:00am, Monday, 03'rd Jan 2022
SOUTH PLAINFIELD, N.J., Jan. 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 40th Annual J.P.
